Catalog No.
Product Name
Application
Product Information
Citations
-
PDE4 Inhibitor
Roflupram is a selective phosphodiesterase 4 (PDE4) inhibitor that demonstrates oral bioavailability and effective central nervous system penetration, with an IC50 of 26.2 nM for human PDE4 core catalytic domains. This compound has been shown to reverse cognitive deficits and decrease the production of pro-inflammatory factors, making it valuable for research applications targeting neurological conditions and inflammation-related pathways. -
Phosphodiesterase (PDE) Inhibitor
K134 is a selective phosphodiesterase 3 (PDE3) inhibitor, demonstrating IC50 values of 0.1 µM for PDE3A and 0.28 µM for PDE3B. Inhibition of PDE3 leads to increased levels of cyclic AMP, which plays a crucial role in various physiological processes. This compound can be used in research applications focused on cardiovascular diseases, as well as in studies investigating the modulation of cellular signaling pathways associated with phosphodiesterase activity. -
PDE5A Inhibitor
Robustine is a furoquinoline alkaloid that acts as a potent inhibitor of human phosphodiesterase 5 (hPDE5A). This compound demonstrates significant inhibitory activity, making it useful for research applications in studying cardiovascular diseases and erectile dysfunction. Its selective targeting of hPDE5A highlights its potential as a therapeutic agent in related fields of investigation. -
PDE7 Inhibitor
PDE7-IN-2 is a selective phosphodiesterase 7 (PDE7) inhibitor with an IC50 value of 2.1 µM. It is primarily utilized in research focused on neurological disorders, particularly Parkinson's disease. By inhibiting PDE7, this compound can elevate intracellular levels of cyclic AMP, potentially influencing neuroprotective pathways and neuroinflammation. -
PDE10A Inhibitor
5,7-Dichloropyrazolo[1,5-a]pyrimidine is a potent inhibitor of phosphodiesterase 10A (PDE10A) with a Ki value of 24 μM. This compound plays a crucial role as an intermediate in the synthesis of 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives, which are investigated for their potential activity as non-nucleoside reverse transcriptase inhibitors against HIV-1. Additionally, 5,7-Dichloropyrazolo[1,5-a]pyrimidine is utilized in research relating to schizophrenia and related neuropsychiatric disorders. -
PDE5 Inhbitor
PDE5-IN-4 is a selective phosphodiesterase 5 (PDE5) inhibitor that plays a significant role in modulating intracellular signaling pathways. It exhibits potential protective effects in various conditions, including acute myocardial infarction, reperfusion injury, gastrointestinal diseases, diabetes-related complications, and liver failure. This compound is valuable for investigating therapeutic strategies in cardiovascular and metabolic disorders. -
PDE7 Inhibitor
PDE7-IN-3 is an inhibitor of the phosphodiesterase PDE7, exhibiting potential analgesic activity. This compound is valuable for investigating various pain models, including inflammatory, neuropathic, visceral, and nociceptive pain. Researchers can utilize PDE7-IN-3 to explore the effects of PDE7 inhibition on pain mechanisms and develop new therapeutic strategies. -
Phosphodiesterase (PDE) Inhibitor
Cirsimarin is a potent phosphodiesterase (PDE) inhibitor derived from Microtea debilis. This flavonoid demonstrates significant antilipogenic activity, effectively reducing adipose tissue deposition in murine models. Its lipolytic effects are attributed to its antagonistic action on adenosine A1 receptors and its ability to inhibit phosphodiesterase activity, making it a valuable compound for research in metabolic disorders and lipid metabolism. -
PDE Inhibitor
Homo Sildenafil is a phosphodiesterase (PDE) inhibitor that enhances intracellular cyclic nucleotide levels. This compound effectively increases nitric oxide signaling, leading to vasodilation and improved blood flow. Homo Sildenafil may be utilized in various research applications, including studies on cardiovascular function and erectile dysfunction therapies. Its structural similarity to Sildenafil makes it a valuable tool for investigating PDE-related pathways and pharmacological effects. -
PDE5 Inhibitor
PDE5-IN-7 is a selective inhibitor of phosphodiesterase 5 (PDE5), demonstrating an IC50 value of 5 nM, and shows considerably lower activity against PDE1 with an IC50 of 300 nM. This compound exhibits potent biological activity in the modulation of intracellular cGMP levels, making it a valuable reagent for research focused on cardiovascular disorders and erectile dysfunction. Its specificity and efficacy make PDE5-IN-7 an important tool for understanding PDE5-related pathways. -
PDE Inhibitor
Imazodan is a selective phosphodiesterase III (PDE III) inhibitor that enhances myocardial contractility by preventing the degradation of cyclic adenosine monophosphate (cAMP). This mechanism leads to improved contractile function in cardiac tissues. Additionally, Imazodan acts as a peripheral vasodilator, making it valuable for research applications related to cardiovascular physiology and pharmacology. -
PDE10A Inhibitor
N-Methylbenzamide is a potent inhibitor of phosphodiesterase 10A (PDE10A), a key enzyme involved in regulating intracellular signaling pathways. This compound exhibits anti-cancer activity by modulating cAMP and cGMP levels, which can influence tumor cell proliferation and survival. N-Methylbenzamide is suitable for research applications investigating PDE10A's role in cancer biology and therapeutic strategies targeting this pathway. -
PDE3B Inhibitor
PDE3B-IN-1 is a selective inhibitor targeting phosphodiesterase 3B (PDE3B) with a pIC50 of 6.5, indicating significant potency. Its >300-fold selectivity for PDE3B over other isoforms makes it a valuable tool for studying the role of PDE3B in cellular signaling and metabolic processes. This compound is primarily utilized in research applications related to cardiovascular diseases, obesity, and diabetes, where modulation of PDE3B activity may provide therapeutic insights. -
PDE Inhibitor
Deltasonamide 2 hydrochloride is a potent inhibitor of phosphodiesterase delta (PDEδ), demonstrating competitive binding with a dissociation constant (Kd) of approximately 385 pM. This compound exhibits significant biological activity in modulating intracellular cyclic nucleotide levels, making it a valuable tool for research in signaling pathways related to cancer, cardiovascular diseases, and metabolic disorders. Its ability to selectively target PDEδ allows for potential applications in studies aimed at understanding the roles of cyclic nucleotides in various physiological processes. -
PDE9 Inhibitor
Irsenontrine is a selective inhibitor of phosphodiesterase 9 (PDE9) with oral bioavailability. It has demonstrated potential in modulating intracellular signaling pathways, making it relevant for exploring therapeutic strategies for neurological diseases. This compound is valuable for research aimed at understanding the role of PDE9 in cognitive function and various neurodegenerative conditions. -
PDE9A Inhibitor
BAY-7081 is a potent and selective inhibitor of phosphodiesterase 9A (PDE9A), demonstrating an IC50 value of 15 nM. This cyanopyridone-based compound exhibits robust oral bioavailability and solubility, making it a valuable tool for investigating the role of PDE9A in various biological processes. Its application in research includes studies on neurodegenerative diseases and cognitive function, where modulation of the cyclic GMP signaling pathway may be beneficial. -
Phosphodiesterase (PDE) Inhibitor
Gisadenafil besylate is a selective phosphodiesterase 5 (PDE5) inhibitor that effectively prevents the degradation of cyclic guanosine monophosphate (cGMP), exhibiting an IC50 of 3.6 nM. This compound is primarily utilized in research related to cardiovascular health and sexual dysfunction, providing insights into the mechanisms regulating vascular smooth muscle relaxation and nitric oxide signaling pathways. Its specificity and oral bioavailability make it a valuable tool for investigating PDE5-related biological processes and therapeutic potential. -
PDE 10 Inhibitor
PDE10-IN-5 is a potent inhibitor of phosphodiesterase 10 (PDE 10), targeting the regulation of intracellular signaling pathways by modulating cyclic nucleotide levels. This compound demonstrates significant biological activity in the central nervous system and is valuable for research on various CNS disorders, including schizophrenia and movement-related diseases. Its specificity for PDE 10 makes it an important tool for elucidating the role of this enzyme in neurodegenerative conditions and potential therapeutic interventions. -
PDE Inhibitor
PF-8380 hydrochloride is a potent phosphodiesterase (PDE) inhibitor, demonstrating an IC50 of 2.8 nM in isolated enzyme assays and 101 nM in human whole blood. This compound is primarily used in research to investigate the role of autotaxin in various biological processes, including inflammation and cancer progression. PF-8380 hydrochloride serves as an important tool for studying the modulation of lysolipid signaling pathways and potential therapeutic interventions targeting autotaxin-related diseases. -
PDE4 Inhibitor
Dovramilast is an orally active phosphodiesterase 4 (PDE4) inhibitor that effectively reduces inflammatory responses. It enhances isoniazid-mediated bacillary clearance from the lungs, making it a valuable adjunct in tuberculosis (TB) research. This compound facilitates studies aimed at understanding and improving therapeutic strategies for TB. -
PDE5 Inhibitor
ent-Tadalafil is the inactive cis-enantiomer of the potent phosphodiesterase type 5 (PDE5) inhibitor (6R,12aS), which exhibits an IC50 of 0.090 μM. While ent-Tadalafil does not demonstrate significant biological activity, its characterization is essential for understanding the structure-activity relationship of PDE5 inhibitors. This compound serves as a reference material in biochemical research and may aid in the evaluation of enantiomeric effects on PDE5 inhibition. -
PDE4 Inhibitor
Tilivapram (AVE8112) is a potent phosphodiesterase 4 (PDE4) inhibitor that demonstrates procognitive effects and enhances processing and psychomotor speeds in vivo. Its oral administration may be associated with dose-related side effects such as nausea and dizziness. However, transdermal delivery offers a controlled elevation of plasma concentrations, minimizing gastrointestinal discomfort and dizziness. Tilivapram is particularly relevant for research into neuropsychiatric disorders and cognitive enhancement. -
PDE9 Inhibitor
(S)-C33 is a highly selective inhibitor of phosphodiesterase-9 (PDE9) with an IC50 value of 11 nM. This compound is primarily utilized in research focused on central nervous system disorders and diabetes. Its significant inhibitory action on PDE9 makes it a valuable tool for investigating the therapeutic potential in these areas. -
PDE5 Inhibitor
Yonkenafil is a potent phosphodiesterase 5 (PDE5) inhibitor that has demonstrated efficacy in reducing cerebral infarction, alleviating neurological deficits, and minimizing edema and neuronal damage in affected areas. Its ability to enhance cognitive function through modulation of neurogenesis indicates potential therapeutic applications in neurodegenerative disorders, including Alzheimer's disease. Researchers may utilize Yonkenafil to investigate its effects on cognitive enhancement and neuroprotection in various experimental models. -
PDE6δ-KRas Inhibitor
Deltasonamide 1 is a potent inhibitor of the PDE6δ-KRas interaction, exhibiting a dissociation constant (KD) of 203 pM. This compound effectively disrupts the function of the KRas signaling pathway, making it a valuable tool for investigating tumor biology and related therapeutic strategies. Deltasonamide 1 holds promise for advancing research in cancer treatment and understanding related pathophysiological mechanisms. -
Phosphodiesterase (PDE)
PDE8B-IN-1 is a selective inhibitor of phosphodiesterase 8B (PDE8B), functioning to enhance insulin secretion. This compound demonstrates notable efficacy in high-throughput screening and has been optimized for ligand efficiency. With high target selectivity and favorable bioavailability observed in preclinical studies, PDE8B-IN-1 holds promise for further investigation into its inhibitory potential in metabolic research. -
PDE4D Inhibitor
PDE4-IN-24 is a highly potent inhibitor of phosphodiesterase 4D (PDE4D) with an IC50 value of 0.57 nM, demonstrating over 4100-fold selectivity against other phosphodiesterase families. This compound is relevant to research on inflammatory diseases, as it modulates cyclic nucleotide signaling pathways, which are critical for controlling inflammation and immune responses. Its specificity and activity make PDE4-IN-24 a valuable tool for studying the role of PDE4D in various biological contexts. -
PDE5 Inhibitor
MBCQ is a selective phosphodiesterase type 5 (PDE5) inhibitor with a potent IC50 of 19 nM. It demonstrates high specificity for cGMP-specific PDE5, exhibiting minimal activity against other phosphodiesterase isozymes (IC50s > 100 μM). MBCQ facilitates the dilation of coronary arteries, making it a valuable reagent for research focused on vascular biology and cardiovascular therapeutics. -
Phosphodiesterase (PDE) Inhibitor
Prinoxodan is a selective phosphodiesterase (PDE) inhibitor that modulates intracellular cAMP levels. This compound has been shown to enhance biological activity in various cellular models, making it a valuable tool for studying signaling pathways involved in cardiovascular and neurological conditions. Prinoxodan is utilized in research applications focused on the regulation of smooth muscle relaxation and the modulation of neurotransmitter release. -
PDE5 Inhibitor
(6S,12aR)-Tadalafil is a potent phosphodiesterase type 5 (PDE5) inhibitor, exhibiting an IC50 value of 5 nM. This compound is known to lower blood pressure and is utilized in research investigating cardiovascular effects, erectile dysfunction therapies, and other related conditions. Its strong inhibitory action on PDE5 makes it a valuable tool for studying nitric oxide signaling pathways and cGMP levels in various biological systems. -
Phosphodiesterase (PDE)
2',3'-Cyclic NADP disodium serves as a substrate for phosphodiesterase (PDE), particularly 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), which is predominantly found in myelin. This compound has been utilized in coupled enzyme assays for the precise quantification of CNP activity. Additionally, 2',3'-Cyclic NADP disodium (at a concentration of 5 μM) has demonstrated the ability to enhance calcium overload-induced calcium release and mitigate calcium-induced swelling in rat brain mitochondria, making it a valuable tool in neurobiological research. -
PDE5 Inhibitor
Carbodenafil is a phosphodiesterase type 5 (PDE5) inhibitor, structurally related to Sildenafil (UK-92480). It effectively inhibits PDE5 with an IC50 of 5.22 nM, leading to increased levels of cyclic GMP and subsequent vasodilation. This compound is primarily utilized in research settings to explore mechanisms associated with erectile dysfunction and pulmonary hypertension. -
PDE Inhibitor
Acetildenafil is a phosphodiesterase type 5 (PDE5) inhibitor that serves as an analogue of Sildenafil. It is primarily used in research to investigate its biological activities related to vasodilation and erectile function. Additionally, Acetildenafil is of interest in studies focusing on its potential therapeutic applications derived from herbal sources. -
PDE5 Inhibitor
Thioquinapiperifil dihydrochloride is a potent and selective non-competitive inhibitor of phosphodiesterase-5 (PDE-5), with an IC50 of 0.074 nM. This compound is primarily utilized in research related to sexual enhancement and erectile function, contributing to studies on the modulation of signaling pathways associated with vasodilation. Its high selectivity and activity make it a valuable reagent for investigating PDE-5's role in various physiological and pathological processes. -
PDE2 Inhibitor
Hcyb1 is a highly selective inhibitor of phosphodiesterase 2 (PDE2), demonstrating an IC50 of 0.57 μM against PDE2A and over 250-fold selectivity towards other members of the phosphodiesterase family. This compound is characterized by its neuroprotective and antidepressant-like effects, which are likely mediated through the cAMP/cGMP-CREB-BDNF signaling pathway. Hcyb1 is a valuable tool for research applications focusing on neurobiology and mood disorders. -
PDE3 Inhibitor
Siguazodan is a selective phosphodiesterase III (PDE-III) inhibitor with an IC50 of 117 nM. It effectively increases cyclic adenosine monophosphate (cAMP) levels in intact platelets, demonstrating an EC50 of 18.88 μM. Additionally, Siguazodan inhibits phenylephrine-induced serotonin (5-HT) release with an IC50 of 4.2 μM, making it a valuable tool for research into cardiovascular and platelet function. -
PDE4B Inhibitor
PDE4B-IN-3 is a potent inhibitor of phosphodiesterase 4B (PDE4B), exhibiting an IC50 of 0.94 μM. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for studies aimed at understanding inflammatory pathways and developing novel therapeutic strategies. It is suitable for use in research applications investigating the role of PDE4B in various diseases, including chronic inflammatory conditions. -
PDE Inhibitor
1-Phenyl-3,4-dihydroisoquinoline is a phosphodiesterase (PDE) inhibitor that demonstrates significant activity in modulating cyclic nucleotide levels. This compound has been investigated for its potential applications in various therapeutic areas, including cardiovascular and neurological research. Its ability to inhibit PDE may provide insights into cellular signaling pathways and support the development of novel pharmacological strategies. -
K-Ras-PDEδ Inhibitor
K-Ras-PDEδ-IN-1 is a selective inhibitor of K-Ras-PDEδ, designed for high-affinity binding to the farnesyl binding pocket of PDEδ with a dissociation constant (Kd) of 8 nM. This compound effectively disrupts the interaction between K-Ras and PDEδ, playing a crucial role in modulating K-Ras signaling pathways. It is valuable for research applications focused on cancer biology and therapeutic strategies targeting K-Ras-driven malignancies. -
PDE4 Inhibitor
LEO 39652 is a potent dual-selective inhibitor of phosphodiesterase type 4 (PDE4), exhibiting IC50 values of 1.2 nM for PDE4A and PDE4B, 3.0 nM for PDE4C, and 3.8 nM for PDE4D. Additionally, it inhibits TNF-α with an IC50 of 6.0 nM. This compound is primarily utilized in topical research for atopic dermatitis (AD), making it valuable for studies aimed at understanding and developing treatments for this condition. -
PDE4 Inhibitor
Lirimilast is a selective and orally active phosphodiesterase-4 (PDE4) inhibitor, exhibiting an IC50 of 49 nM. This compound demonstrates significant anti-inflammatory activity, making it a valuable candidate for therapeutic applications in asthma and chronic obstructive pulmonary disease (COPD). Research utilizing Lirimilast may provide insights into the modulation of inflammatory responses in respiratory conditions. -
PDE2A Inhibitor
PDE2A-IN-3 is a selective inhibitor of phosphodiesterase 2A (PDE2A), exhibiting an IC50 of 69 nM for PDE2A and 1762 nM for PDE10. This compound is valuable for investigating the role of PDE2A in neurological and psychiatric disorders, providing insights into potential therapeutic interventions. Its specificity for PDE2A makes it an essential tool for researchers studying the modulation of cyclic nucleotide signaling pathways associated with these conditions. -
Phosphodiesterase (PDE) Inhibitor
Theodrenaline hydrochloride is a selective phosphodiesterase (PDE) inhibitor that enhances cardiac contractility and improves hemodynamic performance. It exhibits potent cardiac stimulant properties and serves as an effective anti-hypotensive agent, particularly when used in conjunction with Cafedrine. This reagent is valuable for research applications focused on cardiovascular pharmacology and the mechanisms of blood pressure regulation. -
PDE4 Inhibitor
FCPR03 is a highly selective inhibitor of phosphodiesterase 4 (PDE4), demonstrating IC50 values of 60 nM, 31 nM, and 47 nM against the PDE4 catalytic domain, PDE4B1, and PDE4D7, respectively. With over 2100-fold selectivity against other phosphodiesterases (PDE1-3 and PDE5-11), FCPR03 exhibits significant anti-inflammatory, neuroprotective, and antidepressant-like properties. This compound is pivotal for research applications targeting inflammatory and neurodegenerative diseases, as well as mood disorders. -
Phosphodiesterase (PDE) Inhibitor
Theodrenaline is a phosphodiesterase (PDE) inhibitor that functions primarily as a cardiac stimulant. It enhances cardiac contractility and supports blood pressure regulation, making it valuable in the treatment of hypotension. This compound is utilized in cardiovascular research to investigate heart function and the modulation of vascular tone. -
PDE 4 Inhibitor
RS-25344 hydrochloride is a highly selective inhibitor of phosphodiesterase 4 (PDE 4), exhibiting an IC50 of 0.28 nM in human lymphocytes. The compound demonstrates minimal activity against PDE I, II, and III, with IC50 values exceeding 100 μM. RS-25344 hydrochloride possesses significant anti-inflammatory properties and has been shown to enhance memory and cognitive functions, as well as exhibiting potential antineoplastic effects. This makes it a valuable tool for research in areas related to inflammation, neurobiology, and cancer. -
PDE4 Inhibitor
Atizoram is a selective phosphodiesterase 4 (PDE4) inhibitor that elevates cyclic AMP levels while simultaneously reducing tumor necrosis factor-alpha (TNFα) production in murine models. This compound possesses significant anti-inflammatory properties, making it a valuable tool for investigating inflammatory pathways and potential therapeutic strategies in conditions associated with dysregulated TNFα expression. Atizoram is applicable in research exploring the roles of PDE4 in various biological systems and diseases. -
PDE3 Inhibitor
Motapizone is a selective phosphodiesterase 3 (PDE3) inhibitor. It has been shown to moderately inhibit cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages, highlighting its potential anti-inflammatory properties. Additionally, Motapizone enhances intracellular cyclic AMP levels, thereby preventing human platelet aggregation. This compound is valuable for research in inflammation and platelet physiology. -
PDE4 Inhibitor
PDE4-IN-4 is a selective inhibitor of phosphodiesterase 4 (PDE4) with a pIC50 of 8.8, as well as a dual antagonist of the M3 muscarinic receptor with a pIC50 of 10.2. This compound exhibits significant biological activity in modulating cyclic nucleotide levels, making it valuable for research related to pulmonary diseases. Its dual action allows for exploration of therapeutic pathways in respiratory disorders, providing insights into potential treatment strategies. -
PDE3 Inhibitor
Quazinone is a selective inhibitor of cGMP-inhibited phosphodiesterase (PDE3), targeting the catalytic activity of this enzyme. It effectively inhibits the phosphorylation of p42/p44 MAP kinase, leading to decreased mitogenic signaling. Quazinone exhibits antimitogenic effects and is useful in studies related to cell proliferation and signal transduction pathways.
